CN111588848A - 使用贝那利珠单抗降低哮喘恶化率的方法 - Google Patents

使用贝那利珠单抗降低哮喘恶化率的方法 Download PDF

Info

Publication number
CN111588848A
CN111588848A CN202010449434.5A CN202010449434A CN111588848A CN 111588848 A CN111588848 A CN 111588848A CN 202010449434 A CN202010449434 A CN 202010449434A CN 111588848 A CN111588848 A CN 111588848A
Authority
CN
China
Prior art keywords
benralizumab
ser
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010449434.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·沃德
L·罗斯科斯
王冰
D·雷布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN111588848A publication Critical patent/CN111588848A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
CN202010449434.5A 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法 Pending CN111588848A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
US61/864,944 2013-08-12
CN201480043448.XA CN105451760A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480043448.XA Division CN105451760A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Publications (1)

Publication Number Publication Date
CN111588848A true CN111588848A (zh) 2020-08-28

Family

ID=52448837

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010449434.5A Pending CN111588848A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法
CN201480043448.XA Pending CN105451760A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480043448.XA Pending CN105451760A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Country Status (26)

Country Link
US (2) US9441037B2 (enExample)
EP (1) EP3033101B1 (enExample)
JP (4) JP6746495B2 (enExample)
KR (2) KR102390714B1 (enExample)
CN (2) CN111588848A (enExample)
AU (2) AU2014306956B2 (enExample)
BR (1) BR112016002401A8 (enExample)
CA (1) CA2918105C (enExample)
CY (1) CY1122132T1 (enExample)
DK (1) DK3033101T3 (enExample)
ES (1) ES2716906T3 (enExample)
HK (2) HK1221644A1 (enExample)
HR (1) HRP20190405T1 (enExample)
HU (1) HUE042607T2 (enExample)
LT (1) LT3033101T (enExample)
ME (1) ME03348B (enExample)
MX (1) MX368508B (enExample)
PL (1) PL3033101T3 (enExample)
PT (1) PT3033101T (enExample)
RS (1) RS58404B1 (enExample)
RU (1) RU2676333C2 (enExample)
SG (2) SG10202005560UA (enExample)
SI (1) SI3033101T1 (enExample)
SM (1) SMT201900163T1 (enExample)
TR (1) TR201903312T4 (enExample)
WO (1) WO2015023504A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918050C (en) * 2013-08-12 2023-10-03 Medimmune, Llc Methods for improving asthma symptoms using benralizumab
PL3033104T3 (pl) * 2013-08-12 2019-09-30 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
US11542316B2 (en) 2017-01-04 2023-01-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848732A (zh) * 2007-05-14 2010-09-29 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
CN102365017A (zh) * 2009-11-18 2012-02-29 美迪诺亚公司 哮喘急性恶化的治疗及减少哮喘患者住院治疗的可能性
WO2012083132A2 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン5受容体α鎖に対する抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2542042A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Antibody composition specifically binding to il-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
PL3033104T3 (pl) * 2013-08-12 2019-09-30 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
CA2918050C (en) * 2013-08-12 2023-10-03 Medimmune, Llc Methods for improving asthma symptoms using benralizumab

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848732A (zh) * 2007-05-14 2010-09-29 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
CN102365017A (zh) * 2009-11-18 2012-02-29 美迪诺亚公司 哮喘急性恶化的治疗及减少哮喘患者住院治疗的可能性
WO2012083132A2 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Also Published As

Publication number Publication date
JP2024129139A (ja) 2024-09-26
BR112016002401A8 (pt) 2018-06-12
CA2918105A1 (en) 2015-02-19
WO2015023504A8 (en) 2015-09-24
ES2716906T3 (es) 2019-06-17
WO2015023504A1 (en) 2015-02-19
PL3033101T3 (pl) 2019-06-28
AU2014306956A1 (en) 2016-02-04
JP6746495B2 (ja) 2020-08-26
KR20220057637A (ko) 2022-05-09
KR20160042121A (ko) 2016-04-18
CA2918105C (en) 2023-02-28
RU2016108723A (ru) 2017-09-19
JP2020128375A (ja) 2020-08-27
EP3033101A4 (en) 2017-07-12
RU2676333C2 (ru) 2018-12-28
HUE042607T2 (hu) 2019-07-29
ME03348B (me) 2019-10-20
HK1221644A1 (zh) 2017-06-09
HK1225302B (en) 2017-09-08
RU2016108723A3 (enExample) 2018-06-18
MX368508B (es) 2019-10-07
HRP20190405T1 (hr) 2019-04-19
MX2016001383A (es) 2016-08-03
LT3033101T (lt) 2019-03-25
KR102390714B1 (ko) 2022-04-26
EP3033101B1 (en) 2018-12-19
JP2022120009A (ja) 2022-08-17
US20170198049A1 (en) 2017-07-13
SG11201600481UA (en) 2016-02-26
EP3033101A1 (en) 2016-06-22
JP2016527324A (ja) 2016-09-08
SMT201900163T1 (it) 2019-05-10
PT3033101T (pt) 2019-04-02
DK3033101T3 (en) 2019-04-08
BR112016002401A2 (pt) 2017-09-12
SI3033101T1 (sl) 2019-04-30
CN105451760A (zh) 2016-03-30
AU2020201327A1 (en) 2020-03-12
SG10202005560UA (en) 2020-07-29
TR201903312T4 (tr) 2019-04-22
CY1122132T1 (el) 2020-11-25
RS58404B1 (sr) 2019-04-30
AU2014306956B2 (en) 2019-11-21
US9441037B2 (en) 2016-09-13
US20150044202A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
CN111588848A (zh) 使用贝那利珠单抗降低哮喘恶化率的方法
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40035228A (en) Methods for improving asthma symptoms using benralizumab
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40035226

Country of ref document: HK